|
US3964482A
(en)
|
1971-05-17 |
1976-06-22 |
Alza Corporation |
Drug delivery device
|
|
BE795384A
(fr)
|
1972-02-14 |
1973-08-13 |
Ici Ltd |
Pansements
|
|
US5075109A
(en)
|
1986-10-24 |
1991-12-24 |
Southern Research Institute |
Method of potentiating an immune response
|
|
US4897268A
(en)
|
1987-08-03 |
1990-01-30 |
Southern Research Institute |
Drug delivery system and method of making the same
|
|
US5824311A
(en)
|
1987-11-30 |
1998-10-20 |
Trustees Of The University Of Pennsylvania |
Treatment of tumors with monoclonal antibodies against oncogene antigens
|
|
US4870287A
(en)
|
1988-03-03 |
1989-09-26 |
Loma Linda University Medical Center |
Multi-station proton beam therapy system
|
|
US5549910A
(en)
|
1989-03-31 |
1996-08-27 |
The Regents Of The University Of California |
Preparation of liposome and lipid complex compositions
|
|
US5252334A
(en)
|
1989-09-08 |
1993-10-12 |
Cygnus Therapeutic Systems |
Solid matrix system for transdermal drug delivery
|
|
JP3218637B2
(ja)
|
1990-07-26 |
2001-10-15 |
大正製薬株式会社 |
安定なリポソーム水懸濁液
|
|
JP2958076B2
(ja)
|
1990-08-27 |
1999-10-06 |
株式会社ビタミン研究所 |
遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
|
|
US5851795A
(en)
|
1991-06-27 |
1998-12-22 |
Bristol-Myers Squibb Company |
Soluble CTLA4 molecules and uses thereof
|
|
US5846945A
(en)
|
1993-02-16 |
1998-12-08 |
Onyx Pharmaceuticals, Inc. |
Cytopathic viruses for therapy and prophylaxis of neoplasia
|
|
US5801005A
(en)
|
1993-03-17 |
1998-09-01 |
University Of Washington |
Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
|
|
JPH08506247A
(ja)
|
1993-07-09 |
1996-07-09 |
アムジェン ボールダー インコーポレイテッド |
組換えctla4ポリペプチドおよびその製造方法
|
|
US5741516A
(en)
|
1994-06-20 |
1998-04-21 |
Inex Pharmaceuticals Corporation |
Sphingosomes for enhanced drug delivery
|
|
GB9506466D0
(en)
|
1994-08-26 |
1995-05-17 |
Prolifix Ltd |
Cell cycle regulated repressor and dna element
|
|
US5795587A
(en)
|
1995-01-23 |
1998-08-18 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
|
US5697899A
(en)
|
1995-02-07 |
1997-12-16 |
Gensia |
Feedback controlled drug delivery system
|
|
US5738868A
(en)
|
1995-07-18 |
1998-04-14 |
Lipogenics Ltd. |
Liposome compositions and kits therefor
|
|
US5656016A
(en)
|
1996-03-18 |
1997-08-12 |
Abbott Laboratories |
Sonophoretic drug delivery system
|
|
US6451995B1
(en)
|
1996-03-20 |
2002-09-17 |
Sloan-Kettering Institute For Cancer Research |
Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
|
|
US5760395A
(en)
|
1996-04-18 |
1998-06-02 |
Universities Research Assoc., Inc. |
Method and apparatus for laser-controlled proton beam radiology
|
|
US5739169A
(en)
|
1996-05-31 |
1998-04-14 |
Procept, Incorporated |
Aromatic compounds for inhibiting immune response
|
|
US5797898A
(en)
|
1996-07-02 |
1998-08-25 |
Massachusetts Institute Of Technology |
Microchip drug delivery devices
|
|
US5844905A
(en)
|
1996-07-09 |
1998-12-01 |
International Business Machines Corporation |
Extensions to distributed MAC protocols with collision avoidance using RTS/CTS exchange
|
|
US5783208A
(en)
|
1996-07-19 |
1998-07-21 |
Theratech, Inc. |
Transdermal drug delivery matrix for coadministering estradiol and another steroid
|
|
US5779708A
(en)
|
1996-08-15 |
1998-07-14 |
Cyberdent, Inc. |
Intraosseous drug delivery device and method
|
|
EP0970128A1
(en)
|
1997-03-21 |
2000-01-12 |
Brigham And Women's Hospital |
Immunotherapeutic ctla-4 binding peptides
|
|
WO2000014257A1
(en)
|
1998-09-04 |
2000-03-16 |
Sloan-Kettering Institute For Cancer Research |
Fusion receptors specific for prostate-specific membrane antigen and uses thereof
|
|
AU2472400A
(en)
|
1998-10-20 |
2000-05-08 |
City Of Hope |
CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
|
|
ES2706547T3
(es)
|
1998-12-23 |
2019-03-29 |
Pfizer |
Anticuerpos monoclonales humanos para CTLA-4
|
|
NZ517202A
(en)
|
1999-08-24 |
2004-05-28 |
Medarex Inc |
Human CTLA-4 antibodies and their uses
|
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
CA2410510A1
(en)
|
2000-06-02 |
2001-12-13 |
Memorial Sloan-Kettering Cancer Center |
Artificial antigen presenting cells and methods of use thereof
|
|
US7446179B2
(en)
|
2000-11-07 |
2008-11-04 |
City Of Hope |
CD19-specific chimeric T cell receptor
|
|
US7070995B2
(en)
|
2001-04-11 |
2006-07-04 |
City Of Hope |
CE7-specific redirected immune cells
|
|
US20090257994A1
(en)
|
2001-04-30 |
2009-10-15 |
City Of Hope |
Chimeric immunoreceptor useful in treating human cancers
|
|
US20040076955A1
(en)
|
2001-07-03 |
2004-04-22 |
Eos Biotechnology, Inc. |
Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
|
|
GB0203420D0
(en)
|
2002-02-13 |
2002-04-03 |
Oxford Biomedica Ltd |
Peptide
|
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
|
US20050129671A1
(en)
|
2003-03-11 |
2005-06-16 |
City Of Hope |
Mammalian antigen-presenting T cells and bi-specific T cells
|
|
US8353861B2
(en)
|
2003-09-18 |
2013-01-15 |
Texmac, Inc. |
Applicator for applying functional substances into human skin
|
|
EP3530736A3
(en)
|
2005-05-09 |
2019-11-06 |
ONO Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
|
CA2660286A1
(en)
|
2006-08-09 |
2008-02-21 |
Homestead Clinical Corporation |
Organ-specific proteins and methods of their use
|
|
US8389282B2
(en)
|
2007-03-30 |
2013-03-05 |
Memorial Sloan-Kettering Cancer Center |
Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
|
|
PT2170959E
(pt)
|
2007-06-18 |
2014-01-07 |
Merck Sharp & Dohme |
Anticorpos para o receptor humano de morte programada pd-1
|
|
US8479118B2
(en)
|
2007-12-10 |
2013-07-02 |
Microsoft Corporation |
Switching search providers within a browser search box
|
|
PT2242773T
(pt)
|
2008-02-11 |
2017-09-15 |
Cure Tech Ltd |
Anticorpos monoclonais para o tratamento de tumores
|
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
|
JP5173594B2
(ja)
|
2008-05-27 |
2013-04-03 |
キヤノン株式会社 |
管理装置、画像形成装置及びそれらの処理方法
|
|
WO2010014784A2
(en)
|
2008-08-01 |
2010-02-04 |
Bristol-Myers Squibb Company |
Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
|
|
WO2010098788A2
(en)
|
2008-08-25 |
2010-09-02 |
Amplimmune, Inc. |
Pd-i antagonists and methods for treating infectious disease
|
|
TWI469791B
(zh)
|
2009-02-18 |
2015-01-21 |
Oncotherapy Science Inc |
Foxm1胜肽以及含此胜肽之疫苗
|
|
EP2504028A4
(en)
|
2009-11-24 |
2014-04-09 |
Amplimmune Inc |
SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
|
|
EP3053932B1
(en)
|
2010-02-19 |
2020-07-22 |
Xencor, Inc. |
Novel ctla4-ig immunoadhesins
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
WO2012129514A1
(en)
|
2011-03-23 |
2012-09-27 |
Fred Hutchinson Cancer Research Center |
Method and compositions for cellular immunotherapy
|
|
US8398282B2
(en)
|
2011-05-12 |
2013-03-19 |
Delphi Technologies, Inc. |
Vehicle front lighting assembly and systems having a variable tint electrowetting element
|
|
WO2013071154A1
(en)
|
2011-11-11 |
2013-05-16 |
Fred Hutchinson Cancer Research Center |
Cyclin a1-targeted t-cell immunotherapy for cancer
|
|
EP2814846B1
(en)
|
2012-02-13 |
2020-01-08 |
Seattle Children's Hospital d/b/a Seattle Children's Research Institute |
Bispecific chimeric antigen receptors and therapeutic uses thereof
|
|
WO2013126726A1
(en)
|
2012-02-22 |
2013-08-29 |
The Trustees Of The University Of Pennsylvania |
Double transgenic t cells comprising a car and a tcr and their methods of use
|
|
WO2013151664A1
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of proteins
|
|
US10501512B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides
|
|
NZ702108A
(en)
|
2012-05-03 |
2016-09-30 |
Hutchinson Fred Cancer Res |
Enhanced affinity t cell receptors and methods for making the same
|
|
JP2014022858A
(ja)
|
2012-07-17 |
2014-02-03 |
Murata Mfg Co Ltd |
電力増幅器
|
|
LT2884999T
(lt)
|
2012-08-20 |
2021-04-12 |
Fred Hutchinson Cancer Research Center |
Ląstelinės imunoterapijos būdas ir kompozicijos
|
|
WO2014036562A2
(en)
|
2012-08-31 |
2014-03-06 |
University Of Virginia Patent Foundation |
Target peptides for immunotherapy and diagnostics
|
|
RU2729401C2
(ru)
|
2012-10-02 |
2020-08-06 |
Мемориал Слоан-Кеттеринг Кэнсер Сентер |
Композиции и способы для иммунотерапии
|
|
US9308236B2
(en)
|
2013-03-15 |
2016-04-12 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
|
|
CN105682683A
(zh)
|
2013-08-02 |
2016-06-15 |
阿杜罗生物科技控股有限公司 |
结合cd27激动剂以及免疫检查点抑制以用于免疫刺激
|
|
SMT202300039T1
(it)
|
2013-09-13 |
2023-03-17 |
Beigene Switzerland Gmbh |
Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
|
|
KR101714649B1
(ko)
|
2013-10-30 |
2017-03-10 |
한국생명공학연구원 |
암 치료 또는 암 전이 타겟으로서 vgll1의 용도
|
|
IL265834B2
(en)
*
|
2016-10-07 |
2023-03-01 |
Univ Texas |
hla-restricted vgll1 peptides and their use
|